JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Stryker Corp

Затворен

СекторЗдравеопазване

360.47 0.16

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

356.48

Максимум

368.57

Ключови измерители

By Trading Economics

Приходи

-10M

849M

Продажби

1.1B

7.2B

P/E

Средно за сектора

43.878

84.243

EPS

4.47

Дивидентна доходност

0.92

Марж на печалбата

11.839

Служители

53,000

EBITDA

351M

1.7B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+17.4% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.92%

2.28%

Следващи печалби

30.04.2026 г.

Следваща дата на дивидент

29.04.2026 г.

Следваща дата на екс-дивидент

30.03.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

4.3B

141B

Предишно отваряне

360.31

Предишно затваряне

360.47

Настроения в новините

By Acuity

23%

77%

54 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Stryker Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.01.2026 г., 22:05 ч. UTC

Печалби

Stryker Logs Higher 4Q Profit On Sales Gains

30.10.2025 г., 20:36 ч. UTC

Печалби

Stryker Lifts Fiscal Year Sales View After 3Q Revenue Rises

31.07.2025 г., 20:42 ч. UTC

Печалби

Stryker Lifts Guidance on Improving Tariff Outlook

1.05.2025 г., 20:56 ч. UTC

Печалби

Stryker Lowers Adjusted EPS View on $200 Million Tariff Impact

30.01.2026 г., 17:03 ч. UTC

Пазарно говорене

Stryker's 4Q Results Signal 2026 Growth -- Market Talk

29.01.2026 г., 21:07 ч. UTC

Печалби

Stryker Sees 2026 Organic Net Sales Growth 8%-9.5%

29.01.2026 г., 21:05 ч. UTC

Печалби

Stryker 4Q Adj EPS $4.47 >SYK

5.11.2025 г., 19:38 ч. UTC

Печалби

This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

5.11.2025 г., 17:00 ч. UTC

Печалби

This Healthcare Stock Is Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

30.10.2025 г., 20:21 ч. UTC

Печалби

Stryker Lifts FY Sales View After 3Q Revenue Rises

30.10.2025 г., 20:05 ч. UTC

Печалби

Stryker 3Q Adj EPS $3.19 >SYK

30.10.2025 г., 20:05 ч. UTC

Печалби

Stryker 3Q EPS $2.22 >SYK

30.10.2025 г., 20:05 ч. UTC

Печалби

Stryker 3Q Sales $6.1B >SYK

30.10.2025 г., 20:05 ч. UTC

Печалби

Stryker 3Q Net $859M >SYK

30.10.2025 г., 20:05 ч. UTC

Печалби

Stryker Sees FY Adj EPS $13.50-Adj EPS $13.60 >SYK

30.10.2025 г., 20:05 ч. UTC

Печалби

Stryker 3Q Adj EPS $3.19 >SYK

30.10.2025 г., 20:05 ч. UTC

Печалби

Stryker 3Q Net $859M >SYK

30.10.2025 г., 20:05 ч. UTC

Печалби

Stryker 3Q Sales $6.06B >SYK

30.10.2025 г., 20:05 ч. UTC

Печалби

Stryker 3Q EPS $2.22 >SYK

31.07.2025 г., 20:09 ч. UTC

Печалби

Stryker Estimates Net Impact From Tariffs in 2025 of Approximately $175M

31.07.2025 г., 20:09 ч. UTC

Печалби

Stryker Sales >SYK

31.07.2025 г., 20:09 ч. UTC

Печалби

Stryker Sees FY25 Organic Net Sales Up 9.5%-10%

31.07.2025 г., 20:05 ч. UTC

Печалби

Stryker 2Q Sales $6B >SYK

31.07.2025 г., 20:05 ч. UTC

Печалби

Stryker 2Q Net $884M >SYK

31.07.2025 г., 20:05 ч. UTC

Печалби

Stryker Sees FY Adj EPS $13.40-Adj EPS $13.60 >SYK

31.07.2025 г., 20:05 ч. UTC

Печалби

Stryker 2Q EPS $2.29 >SYK

31.07.2025 г., 20:05 ч. UTC

Печалби

Stryker 2Q Adj EPS $3.13 >SYK

31.07.2025 г., 20:05 ч. UTC

Печалби

Stryker 2Q Sales $6B >SYK

31.07.2025 г., 20:05 ч. UTC

Печалби

Stryker 2Q EPS $2.29 >SYK

31.07.2025 г., 20:05 ч. UTC

Печалби

Stryker 2Q EPS $2.29 >SYK

Сравнение с други в отрасъла

Ценова промяна

Stryker Corp Прогноза

Ценова цел

By TipRanks

17.4% нагоре

12-месечна прогноза

Среден 432.21 USD  17.4%

Висок 469 USD

Нисък 387 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Stryker Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

18

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

373.92 / 383.99Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

54 / 352 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Stryker Corp

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
help-icon Live chat